Protein glycation in the kidney: Role in diabetes and aging

Kidney International

Volumn 49, Issue 6, 1996, Pages 1795-1804

  Vlassara, Helen ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

EID: 0030005523     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.270     Document Type: Article

References (69)

1. ADLER S: Diabetic nephropathy: Pathogenesis and treatment. Annu Rev Med 44:303-315, 1993
2. BALLARD DJ, HYMPHREY LL, MELTON LJ, FROHNERT PP, CHU C, ET AL: Epidemiology of persistent proteinuria type II diabetes mellitus. Diabetes 37:405-412, 1988
3. STRIKER GE, PETEN EP, CAROME MA, PESCE CM, SCHMIDT K, YANG CW, ELLIOT SJ, STRIKER LJ: The kidney disease of diabetes mellitus (KDDM): A cell and molecular biology approach. Diabetes/Metabolism Rev 9(1):37-56, 1993
4. UNITED STATES RENAL DATA SYSTEM: USRDS 1995 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease. Bethesda, Maryland; April 1995
5. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
6. BUCALA R, VLASSARA H, CERAMI A: Advanced glycosylation endproducts, in Post Translational Modification of Proteins, edited by HARDING JJ, CRABBE MJC, Boca Raton, FL, CRC Press, 1992, 2:53-79
7. VLASSARA H, BUCALA R, STRIKER L: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. J Lab Invest 70(2):138-151, 1994
8. MAKITA Z, RADOFF S, RAYFIELD EJ, YANG Z, SKOLNIK E, FRIEDMAN EA, CERAMI A, VLASSARA H: Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
9. MAKITA Z, BUCALA R, RAYFIELD EJ, FRIEDMAN EA, KAUFMAN AM, KORBET SM, BARTH RH, WINSTON JA, FUH H, MANOGUE KR, CERAMI A, VLASSARA H: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
10. KORBET S, MAKITA Z, FIRANEK CA, VLASSARA H: Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. Am Kidney Dis 22(4):588-591, 1993
11. SELL DR, NAGARAJ RH, GRANDHEE SK, ODETTI P, LAPOLLA A, FOGARTY J: Pentosidine-a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev 7:239-251, 1991
12. BUCALA R, MAKITA Z, VEGA G, GRUNDY S, KOSCHINSKY T, CERAMI A, VLASSARA H: Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445, 1994
13. 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
14. 2-microglobulin modified with advanced glycation endproducts in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93:521-527, 1994
15. BAILEY AJ, SIMS TJ, AVERY NC, MILES CA: Chemistry of collagen crosslinks-glucose-mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J 296:489-496, 1993
16. FU MX, WELL-KNECHT KJ, BLACKLEDGE JA, LYONS TJ, THORPE SR, BAYNES JW: Glycation, glycosidation, and cross-linking of collagen by glucose: Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43:676-683, 1994
17. DYER DG, BLACKLEDGE JA, THORPE SR, BAYNES JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose-identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-11660, 1991
18. NAKAMURA K, HASEGAWA T, FUKUNAGA Y, LENAGA K: Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of α-N-acetyl-L-lysine with D-glucose. J Chem Soc Chem Commun 992-994, 1992
19. NAKAYAMA H, TANEDA S, KUWAJIMA S, AOKI S, KURODA Y, MISAWA K, NAKAGAWA S: Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Comm 162:740-745, 1989
20. HORIUCHI S, ARAKI N, MORINO Y: Immunochemical approach to characterize advanced glycation endproducts of the Maillard reaction. J Biol Chem 266:7329-7332, 1991
21. MAKITA Z, VLASSARA H, CERAMI A, BUCALA R: Immunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 267:5133-5138, 1992
22. BROWNLEE M, VLASSARA H, KOONEY A, ULRICH P, CERAMI A: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 232:1629-1632, 1986
23. BUCALA R, TRACEY KJ, CERAMI A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438, 1991
24. DE TEJADA IS, GOLDSTEIN I, AZADZOI K, KRANE RJ, COHEN RJR: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle in diabetic men with impotence. N Engl J Med 320:1025-1030, 1989
25. MCVEIGH GE, BRENNAN GM, JOHNSTON GD, MCDERMOTT BJ, MCGRATH LT, HENRY WR, ANDREWS JW, HAYES JR: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 35:771-776, 1992
26. GASCHO JA, FANELLI C, ZELIS R: Aging reduces venous distensibility and the venodilatory response to nitroglycerin in normal subjects. Am J Cardiol 63:1267-1270, 1989
27. VLASSARA H, FUH H, MAKITA Z, KRUNGKRAI S, CERAMI A, BUCALA R: Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal adults: A model for diabetic and aging complications. Proc Natl Acad Sci USA 89:12043-12047, 1992
28. HOGAN M, CERAMI A, BUCALA R: Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. J Clin Invest 90:1110-1115, 1992
29. BUCALA R, MAKITA Z, KOSCHINSKY T, CERAMI A, VLASSARA H: Lipid advanced glycosylation. Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438, 1993
30. VLASSARA H, BROWNLEE M, CERAMI A: High-affinity receptor-modified uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588-5592, 1985
31. VLASSARA H, BROWNLEE M, CERAMI A: Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 164:1301-1309, 1986
32. YANG Z, MAKITA Z, HORII Y, BRUNELLE S, CERAMI A, SEHAJPAL P, SUTHANTHIRAN M, VLASSARA H: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins. J Exp Med 174:515-524, 1991
33. SILBERSTEIN S, KELLEHER DJ, GILMORE R: The 48-kDa subunit of the mammalian oligosaccaryltransferase complex is homologous to the essential yeast protein WBP1. J Biol Chem 267(33):23658-23663, 1992
34. r 87,000 protein kinase C substrate from rat brain. J Biol Chem 262(34):16686-16691, 1987
35. LI YM, MITSUHASHI T, WOJCIECHOWICZ D, GILMORE R, VLASSARA H: Elucidation of advanced glycation-receptor components p60/OST-48 and p90/80 K-H. Diabetes 44(1):113A, 1995
36. KIRSTEIN M, BRETT J, RADOFF S, STERN D, VLASSARA H: Advanced glycosylation endproducts selectively induce monocyte migration across intact endothelial cell monolayers, and elaboration of growth factors: Role in aging and diabetic vasculopathy. Proc Natl Acad Sci USA 87:9010-9014, 1990
37. VLASSARA H, BROWNLEE M, MANOGUE KR, PASAGIAN A, DINARELLO CA: Cachetin/TNF and II-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 240:1546-1548, 1988
38. IMANI F, HORII Y, SUTHANTHIRAN M, SKOLNIK EY, MAKITA Z, SHARMA V, SEHAJPAL P, VLASSARA H: Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-γ: Role in tissue remodeling. J Exp Med 178:2165-2172, 1993
39. LIBBY P, HANSSON GK: Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. J Lab Invest 64:5-15, 1991
40. ESPOSITO C, STERN D, GERLACH H, VLASSARA H: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170:1387-1407, 1989
41. SCHMIDT AM, VIANNA M, GERLACH M, BRETT J, RYAN J, KAO J: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 256(21):14987-14997, 1992
42. NEEPER M, SCHMIDT AM, BRETT J, YAN SD, WANG F, PAN YCE, ET AL: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-145004, 1992
43. BRETT J, SCHMIDT AM, YAN SD, ZOU YS, WEIDMAN E, PINSKY D, NOWYGROD R, NEEPER M, PRZYSIECKE C, SHAW A, MIGIHEL A, SIERN D: Survey of the distribution of a newly charaterized receptor for advanced glycation end products in tissues. Am J Pathol 143(6):1699-1712, 1993
44. VLASSARA H, LI YM, IMANI Y, WOJCIECHOWICZ D, YANG A, LIU F-T: Identification of Galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol Med 1(6):634-646, 1995
45. SKOLNIK EY, YANG Z, MAKILA Z, RADOLF S, KIRSLEIN M, VLASSARA H: Human and rat mesangial cell receptors for glucose-modified proteins: Potenlial role in kidney tissue remodeling and diabectic nephropathy. J Exp Med 174:931-939, 1991
46. DOI T, VLASSARA H, KIRSTEIN M, YAMADA Y, STRIKER GE, STRIKER LJ: Receptor-specific increased mesangial cell extracellular matrix production is mediated by PDGF. Proc Natl Acad Sci USA 89:2873-2877, 1992
47. YANG CW, VLASSARA H, PETEN EP, HE CJ, STRIKER LJ: Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91(20):9436-9440, 1994
48. VLASSARA H, STRIKER LJ, TEICHBERG S, FUH H, LI YM, STEAFFS M: Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708, 1994
49. VLASSARA H, FUH H, DONNELLY T, CYBUTSKY M: Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1(4):447-456, 1995
50. NICHOLES K, MANDEI TE: Advanced glycosylation endproducts in experimental murine diabetic nephropathy: Effect of islet isografting and of aminoguanidine. J Lab Invest 60:486-491, 1989
51. ELLIS EN, GOOD BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991
52. SOULIS-LIPAROLA T, COOPER M, PAPAZOGLOU D, CLARKE B, JERUMS G: Retardation by aminoguanidine of development of albuminuria, mesagial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
53. EDELSIFIN D, BROWNLEE M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35:96-97, 1992
54. IUAKURA M, YOSHIKAWA H, BANNAL C, KAIO M, KUNIKA K, KAWAKAMI Y, TAMAOKA T, YAMASHITA K: Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci 49:889-897, 1991
55. CHO HK, KOZU H, PEYMAN GA, PARRY GJ, KHOOBEIH B: The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats. Ophthalmic Surg 22:44-47, 1991
56. HAMMES HP, MARTIN S, FEDERLIN K, GEISEN K, BROWNLEE M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558, 1991
57. HAMMES H-P, BROWNLEE M, EDELSIFIN D, SALECK M, MARTIN S, FEDERIN K: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37:32-35, 1994
58. HUBBERTS MSP, WOLFFENBUTTH BHR, STRUIJNER-BOUDIER HAJ, CRUNS FRL: Aminioguandine treatment increases elasticity and decreases fluid retention of large arteries from diabetic rats. J Clin Invest 92:1407-1411, 1993
59. HUBBERTS MSP, WOLLFENBUTTH, BHR, CRUNS FRL, NIEUWENHUTTZEN KRUSEMAN AC, BEMELMANS MHA, STRULIKER BOUDIER HAJ: Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 37:10-14, 1994
60. KIHARA J, SCHMEITZER JD, PODUSIO JF, CURRAN GL, NICKVINDER KK, LOW PA: Aminoguianidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88:6107-6111, 1991
61. YAGIHASHI S, KAMIJO M, BABA M, YAGIHASHI N, NAGAI K: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52, 1992
62. CAMERON NE, COFFER MA, DINES K, LOVE A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946-950, 1992
63. ODELH PR, BORGOGLIO A, DE PASCALE A, ROLANDI R, ADEZAMI L: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39:796-801, 1990
64. OXLUND H, ANDREASSIN TT: Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. Diabetologia 35:75-78, 1992
65. MAKITA Z, VLASSARA H, RAYFIELD E, CARTWRIGHT K, FRIEDMAN E, RODBY R, CERAMI A, BUCALA R: Hemoglobin-AGE: A circulating marker of advanced glycosylation. Science 258:651-653, 1992
66. FISHBANE S, BUCALA R, KOSCHINKSY T, GIORDANO D, FOUNDS H, VLASSARA H: Significant reduction of plasma LDL-Apo B and glycated Apo B follows chronic high-flux hemodialysis in diabetic uremic patients (abstract). J Am Soc Nephrol 6:487, 1995
67. GIARDINO I, EDELSTEIN D, BROWNLEE M: Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 94:110-117, 1994
68. LI YM, STEFFES M, DONELLY T, EL AL : Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA, in press
69. WOLFENBUTTEL BHR, GIORDANO D, FOUNDS HW, BUCALA R: Long-term assessment of glucose control by hemoglobin-AGF: measurement. Lancet 347:513-515, 1996